Corneal Neovascularization clinical trials
The registry lists 29 studies for Corneal Neovascularization across 8 countries. 4 are recruiting or about to start. 26 of them are mainly about Corneal Neovascularization (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-17.
Get an email when these change. Save the Corneal Neovascularization studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Reza Dana, MD (5) · Massachusetts Eye and Ear Infirmary (2) · Zhongshan Ophthalmic Center, Sun Yat-sen University (2) · Balamurali Ambati (1) · Medical College of Hampton Roads (1) · Asociación para Evitar la Ceguera en México (1) · University of Utah (1) · Medical University of Vienna (1)
What is being tested here
Drugs under test in Corneal Neovascularization studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Bevacizumab | 1 | 1 | 10 |
| Ranibizumab | 0 | 0 | 2 |
| Aflibercept | 0 | 0 | 2 |
| Pazopanib | 0 | 0 | 1 |
| Interleukin 1 Receptor Antagonist Protein | 0 | 0 | 1 |
| Immunoglobulins, Intravenous | 0 | 0 | 1 |
| Immunoglobulin G | 0 | 0 | 1 |
Drug classes tested here Angiogenesis inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 3 Corneal Neovascularization studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 29 studies, recruiting or not: 31% stop at 75 or younger and 10% at 65; 10% take children; 0% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 29 of 29. search them.
- Corneal Crosslinking for Treatment of Corneal NeovascularizationRecruitingNCT04787471Phase 2/31 country
- Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal NeovascularizationRecruitingNCT07642960Not applicable1 country
- Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.RecruitingNCT07329686Phase 1/21 country
- Validation of Human Drugs Target of Repurposed Drugs and Novel TherapiesNot yet recruitingNCT06412718
- Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) GraftCompletedNCT02592330Phase 1/21 country
- Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal NeovascularizationCompletedNCT00555594Phase 2/31 country
- Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.Status unknownNCT056599401 country
- Topical Avastin for Treatment of Corneal NeovascularizationCompletedNCT00559936Phase 11 country
- Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot StudyCompletedNCT01843101Phase 21 country
- The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal NeovascularizationStatus unknownNCT05011916Phase 1/21 country
- Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic AssessmentStatus unknownNCT04620109Phase 11 country
- A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant SurvivalCompletedNCT01996826Phase 1/21 country
- An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal NeovascularizationStatus unknownNCT04215393Phase 11 country
- Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal NeovascularizationTerminatedNCT02797704Phase 1/21 country
- Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant SurvivalCompletedNCT01072357Phase 1/21 country
- Treatment of Corneal Neovascularization With Topical PazopanibCompletedNCT01257750Phase 1/21 country
- Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant SurgeryCompletedNCT00769145Phase 11 country
- Topical IL-1-Ra for Treatment of Corneal NeovascularizationTerminatedNCT00915590Phase 1/21 country
- Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory ConditionsWithdrawnNCT02042027Phase 11 country
- Strategies for Management of Corneal NeovascularisationStatus unknownNCT02594423Phase 4
- Using Aflibercept Injection to Treat Blood Vessel Growth Over the CorneaTerminatedNCT01868360Phase 11 country
- Corneal Thinning During Topical Bevacizumab TherapyWithdrawnNCT00515684Not applicable1 country
- Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal NeovascularizationCompletedNCT00004430Not applicable1 country
- Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal NeovascularizationCompletedNCT00512876Not applicable1 country
- Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)CompletedNCT00681889Phase 11 country
- The Effect of Bevacizumab on Corneal NeovascularizationCompletedNCT00797303Phase 4
- Bevacizumab for the Treatment of Corneal NeovascularizationStatus unknownNCT00992849Phase 21 country
- Photodynamic Therapy With Verteporfin for Corneal NeovascularizationCompletedNCT00471406Not applicable
- Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal NeovasculizationCompletedNCT00681603Not applicable1 country